close

Agreements

1 2 3 4 5 245
Number of results: 4881

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2018-10-04 Arrowhead Pharmaceuticals (USA - CA) Janssen Pharmaceutical, a J&J Company (USA)
  • ARO-HBV and up to three additional RNA interference (RNAi) therapeutics
hepatitis B licensing - research Infectious diseases Licensing agreement
2018-10-04 Horizon Discovery (UK) Celyad (Belgium) shRNA technology licensing Technology - Services Licensing agreement
2018-10-03 Boston Pharmaceuticals (USA - MA) Novartis (Switzerland) LYS228, IID572, MAK181 carbapenem-resistant enterobacteriaceae (CRE) infections, Pseudomonas infections licensing Infectious diseases Licensing agreement
2018-10-03 Boston Pharmaceuticals (USA - MA) GSK (UK) GSK3352589, GSK3008356, GSK3183475 and two undisclosed preclinical programs acne, irritable bowel syndrome with diarrhea (IBS-D) licensing Autoimmune diseases - Dermatological diseases - Digestive Diseases - Inflammatory diseases Licensing agreement
2018-10-03 Trovagene (USA - CA) Massachusetts Institute of Technology (MIT) (USA - MA) combination therapies that include anti-androgen or androgen antagonist and a Polo-like Kinase (PLK) inhibitor licensing Cancer - Oncology Licensing agreement
2018-10-03 Cellular Biomedicine Group (China) National Cancer Institute (USA) next generation neoantigen-reactive tumor infiltrating lymphocyte (“TIL”) technology licensing Cancer - Oncology Licensing agreement
2018-10-02 Kite Pharma (USA - CA), a Gilead company (USA - CA) HiFiBiO Therapeutics (USA - MA) neoantigen-reactive T cell receptors (TCRs) for the treatment of various cancers research - licensing Cancer - Oncology Licensing agreement
2018-10-02 Cytosen Therapeutics (USA - TX) KBI Biopharma (USA - NC) Natural Killer (NK) cells bioproduction - manufacturing Cancer - Oncology - Technology - Services Production agreement
2018-10-01 Editas Medicine (USa - MA) senior vice president nomination Rare diseases - Genetic diseases - Ophtalmological diseases Nomination
2018-10-01 Melinta Therapeutics (USA - CT) Menarini (Italy) Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible designated gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia, bacteraemia that occurs in association with any of these infections and infections due to aerobic Gram-negative organisms, infections due to susceptible strains of important designated gram-positive and gram-negative pathogens, including infections due to Acinetobacter species licensing - development - commercialisation Infectious diseases Licensing agreement
2018-10-01 KangStem Biotech (South Korea) MaSTherCell, (Belgium), a subsidiary of Orgenesis (USA - NY) Furestem-AD® manufacturing - bioproduction Technology - Services Production agreement
2018-09-27 Editas Medicine (USA - MA) chief medical officer resignation Rare diseases - Genetic diseases - Ophtalmological diseases Resignation
2018-09-27 Cellular Biomedicine Group (China) Novartis (Switzerland) Kymriah® - CTL019 (tisagenlecleucel-T) manufacturing - production Cancer - Oncology - Technology - Services Production agreement
2018-09-27 Cellular Biomedicine Group (China) Novartis (Switzerland) Kymriah® - CTL019 (tisagenlecleucel-T) manufacturing - production Cancer - Oncology - Technology - Services Production agreement
2018-09-27 Allogene Therapeutics (USA - CA) member of the board of directors nomination Cancer - Oncology Nomination
2018-09-27 BioInvent (Sweden) Cardiovax (USA - CA) orticumab (BI-204) production - manufacturing Inflammatory diseases - Technology Services Production agreement
2018-09-26 Celyad (Belgium) vice president nomination Cancer - Oncology Nomination
2018-09-25 Cobra Biologics (Sweden) Centre for Process Innovation (CPI) (UK) GE Healthcare Life Sciences (USA - WI) manufacturing of adeno-associated virus (AAV) vectors collaboration Technology - Services Collaboration agreement
2018-09-25 KSQ Therapeutics (USA - MA) member of the board of directors nomination Cancer - Oncology Nomination
2018-09-21 InflaRx (Germany) member of the board nomination Inflammatory diseases Nomination